|View printer-friendly version|
Array BioPharma Reports Financial Results For The Second Quarter of Fiscal 2002
During the second quarter of fiscal 2002, total revenue reached $8.4 million, up 118% from $3.8 million during the same period in fiscal 2001. Net loss was $1.3 million or ($0.05) per share, compared to a net loss of $4.2 million or ($0.33) per share for the comparable quarter in fiscal 2001. Array ended the second quarter of fiscal 2002 with $36.8 million in cash and marketable securities.
"We continued our revenue growth this quarter and achieved a positive cash flow from operations, which excludes investment in facilities and equipment," said Robert E. Conway, Chief Executive Officer. "We intend to utilize this cash flow to increase our investment in Array's proprietary research, creating a pipeline of early drug discovery programs aimed at families of therapeutically important disease targets including kinases, phosphatases and proteases. Our strategy is to continue to enhance the capabilities of the Array Discovery Platform, creating value for both our collaborators and our own proprietary research."
Highlights during the second quarter of fiscal 2002 include: -- Increased revenues by 118% compared to the same period in the last fiscal year, primarily as a result of new and expanded collaborations. -- In collaboration with ICOS Corporation, our first drug discovery agreement has resulted in a clinical candidate. In November 2001, ICOS initiated clinical trials with IC485 and subsequently made a milestone payment to Array. -- Signed a series of non-exclusive agreements to provide Pfizer Inc with access to chemical compounds from the Array Discovery Platform for its internal drug discovery programs. To date, this series of agreements positions Pfizer as one of Array's top five collaborators for fiscal year 2002. -- Amgen Inc. initiated a new drug discovery program with Array. The new program replaces the existing PTP-1B collaboration that was announced in November 2000. Array retains all rights to the existing PTP-1B program. -- Shipped $1.0 million of Optimer(TM) building blocks to a single major pharmaceutical company, fueling a record quarter of Optimer sales, which totaled $1.5 million. -- Achieved for the first time positive quarterly earnings before interest, taxes, depreciation and amortization (EBITDA) of $109,000, which is the net loss of $1.3 million, excluding interest income of $351,000, depreciation of $1.1 million, and amortization from compensation related to option grants of $644,000.Revenue for the six-month period ended December 31, 2001, was $15.6 million, increasing 136% compared to revenues of $6.6 million for the same period in fiscal 2001. The net loss for the six months ended December 31, 2001, was $2.8 million, or ($0.12) per share, compared to a net loss of $12.3 million, or ($1.49) per share, reported in the same period in fiscal 2001.
Array will hold a conference call on Wednesday, January 23, 2002, at 9:00 a.m. eastern time to discuss these results. Robert E. Conway, Chief Executive Officer and Michael Carruthers, Chief Financial Officer, will lead the call.
CONFERENCE CALL INFORMATION Date: Wednesday, January 23, 2002 Time: 9:00 a.m. eastern time Toll-Free: (888) 515-2235 Toll: (719) 457-2601 Web Cast: www.arraybiopharma.comThere will be a replay of the conference call for one week, which can be accessed in the United States by dialing toll-free (888) 203-1112, and outside the United States (719) 457-0820. The access code is 511940. Replay of the call will also be available as a web cast on Array's web site at www.arraybiopharma.com .
About Array BioPharma:
Array BioPharma is a drug discovery company inventing new drugs through the integration of chemistry, biology and informatics. We collaborate with leading pharmaceutical and biotechnology companies to identify novel small molecule drugs using the Array Discovery Platform. We leverage this integrated approach to small molecule drug discovery to develop our own pipeline of proprietary drug candidates. For more information on Array BioPharma, please visit our web site at www.arraybiopharma.com .
EBITDA means earnings before interest, taxes, depreciation and amortization. EBITDA should be considered in addition to, but not as a substitute for, loss from operations, net loss and other measures of financial performance prepared in accordance with generally accepted accounting principles that are presented in Array's financial statements. Array's calculation of EBITDA may be different from the calculation used by other companies and therefore, may not be comparable to similarly titled measures reported by other companies.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties, including those discussed below and described more fully in reports filed by Array with the Securities and Exchange Commission, including our Annual Report on Form 10-K as filed on September 27, 2001. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to collaborate with third parties on their drug discovery activities, the ability of our collaborators and of Array to meet drug discovery objectives tied to milestones and royalties, our ability to create successful proprietary drug candidates and our ability to attract and retain experienced scientists and management. We are providing this information as of January 22, 2002. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.
Array BioPharma Inc. Condensed Statement of Operations (in thousands, except per share amounts) Three Months Ended Six Months Ended December 31, December 31, 2001 2000 2001 2000 (unaudited) (unaudited) Revenue $8,358 $3,833 $15,550 $6,594 Cost of revenue* 5,004 3,291 9,537 5,699 Gross profit 3,354 542 6,013 895 Research, and development expenses* 3,262 2,115 6,047 3,817 Selling, general and administrative expenses* 1,720 2,955 3,549 4,649 Total operating expenses 4,982 5,070 9,596 8,466 Loss from operations (1,628) (4,528) (3,583) (7,571) Interest expense -- (180) -- (353) Interest income 351 477 812 607 Net loss (1,277) (4,231) (2,771) (7,317) Deemed dividend related to beneficial conversion feature of preferred stock -- -- -- (5,000) Net loss applicable to common stockholders $(1,277) $(4,231) $(2,771) $(12,317) Basic and diluted net loss per share applicable to common stockholders $(0.05) $(0.33) $(0.12) $(1.49) Shares used in computing basic and diluted net loss per share 23,516 12,855 23,434 8,287 * Includes compensation related to option grants: Cost of revenue $271 $277 $542 $486 Research and development expenses 180 163 360 302 Selling, general and administrative expenses 193 2,191 442 2,548 Total $644 $2,631 $1,344 $3,336 Summary Balance Sheet Data (in thousands) December 31, June 30, 2001 2001 (unaudited) Cash, cash equivalents and marketable securities $36,824 $47,712 Property, plant and equipment, net 27,349 17,421 Working capital 34,073 44,917 Total assets 73,687 70,950 Stockholders' equity 61,598 62,468SOURCE Array BioPharma Inc.
CONTACT: Tricia Haugeto of Array BioPharma Inc., +1-303-386-1193, or firstname.lastname@example.org